Xencor, Inc.
BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28

Abstract:

Provided herein are novel .alpha.PD-L1 antibodies and methods of using such antibodies for the treatment of cancers. In some embodiments, the antibodies are .alpha.PD-L1.times..alpha.CD28 bispecific antibodies. Such antibodies enhance anti-tumor activity by providing a costimulatory signal for T-cell activation against tumor cells while advantageously also blocking inhibitory PD-L1:PD-1 pathway interactions.